Truth, Inspiration, Hope.

BUSINESS

Evergrande-Group-Debt-crisis-offshore-investors-not-priority-getty-images-1345348075
Offshore Investors in Trouble as Evergrande Favoring Domestic Obligations
With liabilities of more than $300 billion, China’s Evergrande Group is the one of most indebted property...
new-york-stock-exchange-us-flags
The Silent Influence of the ‘China Model’ on US Economic Policy
Most analyses of the Chinese economy belong to one of two types: those that come from the venture capital...
cargo-supply chains-Biden-Biden administration-Labour Department-Producer Price Index-inflation-hyperinflation-shortage-Food Prices-Rent-Fuel-Federal Reserve-crisis-Getty-Images-1346437290
COVID-19 Crisis Fans Inflation of Food Prices, Rent, and Fuel
Consumer prices rose 8.6 percent last year induced by skyrocketing energy tariffs that are further hampering...
Moderna-Pfizer-Johnson & Johnson-Janssen-booster-shot-J&J-vaccine-COVID-19-Getty-Images-1232608690
FDA Weighs Endorsing a Johnson & Johnson Booster Shot
On Oct. 13, U.S. drug regulators said a second shot of Johnson & Johnson’s single-shot COVID-19 vaccine...
Southwest Airlines Cancels More Than 1800 Flights; Blames Air Traffic Control Issues, Weather
Since Friday, Southwest Airlines has canceled more than 1800 flights, igniting speculation about a massive...
A contact tracing QR code is seen at the entrance of a restaurant in Sydney on July 13, 2021. Rashays, a 27-location chain based in Sydney, says it will not reopen its doors when the New South Wales government relaxes restrictions on Oct. 1. Instead, Rashays will wait until Dec. 1 when vaccine passports are scheduled to be scrapped entirely. Co-founder Rami Ykmour said his company expects to lose $10 million during the delay, but feels the sacrifice is worth it for their business values.
Australian Restaurant Chain Expects to Lose $10 Million to Postpone Reopening Until ‘It’s a One-tier
A 27-location restaurant chain in Australia’s New South Wales (NSW) state will remain closed after the...
The headquarters of Merck in Darmstadt on November 22, 2019 in Germany. Merck’s antiviral COVID-19 pill, molnupiravir, was developed with $35 million in NIH and NIAID taxpayer funding at Emory University. Now, Merck is selling it back to the government at 35 times the cost of its generic counterpart.
The NIAID and NIH Financed Development of Merck’s COVID Pill, Now They’re Selling to Taxpayers at 3,500%
Merck’s recently announced pill-based antiviral treatment for COVID-19 was researched and developed at...
Made-in-China Passenger Jet Comes With 40 Percent Foreign Components
The Commercial Aircraft Corp of China (COMAC) is set to deliver its first large passenger jet, the C919...
evergrande-domino-effect-china
China’s Evergrande Crisis Could Lead to a Massive Domino Effect in Real Estate
Commentary by Cheng Xiaonong An overarching illusion about China's prosperity concerns the "construction...